Akari therapeutics plc (AKTX)
Income statement / Yearly
Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10
Operating Expenses:
Research and development costs

23,285

17,306

5,799

1,616

1,276

1,483

841

247

General and administrative expenses

11,798

9,940

5,502

303

2,330

2,184

1,406

545

Litigation settlement loss

2,700

0

0

-

-

-

-

-

Excess consideration

0

0

19,283

0

-

-

-

-

Total Operating Expenses

37,784

27,246

30,584

1,919

-

-

-

-

Loss from Operations

-37,784

-27,246

-30,584

-1,919

-3,606

-3,667

-2,247

-792

Other Income (Expense):
Interest income

175

143

20

0

-

-

-

-

Changes in fair value of option and warrant liabilities (loss) gain

2,581

8,733

11,408

0

-

-

-

-

Foreign currency exchange gain (loss)

-358

272

-90

-

-

-

-

-

Financing expense

0

0

22,973

0

-

-

-

-

Foreign currency exchange gains/(losses)

-

-

-

-22

-

-

-

-

Interest expense

0

0

3,053

5

-

-

-

-

Other expenses

13

43

44

0

-

-

-

-

Total Other Income (Expense)

2,384

9,105

-14,732

-28

-

-

-

-

Financial expense (income), net

-

-

-

-

-14

-601

128

117

Net Loss

-35,399

-18,140

-45,317

-1,947

-3,620

-4,268

-2,119

-675

Other Comprehensive Loss:
Foreign Currency Translation Adjustment

43

-436

110

79

-

-

-

-

Comprehensive Loss

-35,355

-18,577

-45,207

-1,868

-

-

-

-

Deemed dividend related to warrants modification

-

-

-

-

0

33

0

0

Net loss attributable to holders of ordinary shares

-

-

-

-

-3,620

-4,301

-2,119

-675

Loss per common share (basic and diluted)

-0.03

-0.02

-0.05

-0.02

-0.17

-0.35

-0.18

-0.06

Weighted average common shares (basic and diluted)

1,247,293

1,177,693

852,088

85,515

-

-

11,920

11,420

Weighted average number of ordinary shares used in computing basic net loss per share (in shares)

-

-

-

-

21,075

12,458

-

-

Weighted average number of shares of ordinary shares used in computing diluted net loss per share (in shares)

-

-

-

-

21,075

12,458

-

-